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Summary We have investigated the mechanism of resistance to adriamycin (ADR) of 3 human glioma cell
lines in culture. The cell lines had different inherent sensitivities to ADR. Verapamil increased the ADR
sensitivities of the 2 most resistant cell lines (G-UVW and G-CCM) by up to 5-fold. This effect was not seen
in a sensitive cell line (G-MCF). Although the accumulation of ADR in the 3 cell lines was not related to
inherent sensitivity, energy deprivation or the addition of verapamil produced an increase (up to 46%) in net
uptake for both G-UVW and G-CCM, but not for G-MCF. For G-UVW the ADR efflux data were
consistent with an energy-dependent ADR efflux mechanism which could be inhibited by verapamil. A similar
mechanism was not found for G-CCM. In this cell line verapamil may act by increasing intracellular ADR
binding. These data indicate that, while inherent resistance to ADR may be multifactorial, one possible
mechanism of resistance in human glioma may involve changes in drug accumulation and/or binding as has
been seen in animal models. A potential clinical role for verapamil in overcoming drug resistance in human
solid tumours is also indicated.
Previously we have investigated the inherent
sensitivity of six cell lines established from
individual cases of human glioma to the cytotoxic
drugs adriamycin (ADR), actinomycin D (AD),
VP16-213 (VP16), vincristine (VC), L-phenylalanine
mustard (melphalan, L-PAM) and 5-fluorouracil (5-
FU) (Merry et al., 1984). We demonstrated a
similar pattern of cross-resistance to the drugs AD,
VP16, VC and (to some extent) ADR as has been
found in a number of animal tumour models and in
human haemopoietic cell lines. This phenomenon
has been termed pleiotropic drug resistance (PDR)
and defective membrane transport (possibly
enhanced drug efflux) has been postulated as a
major factor underlying this resistance (for review
see Chabner et al., 1983).
An important characteristic of PDR is the
reversal of resistance by calcium antagonists and
calmodulin inhibitors. Much of this work has been
done using the P388 mouse leukaemia model where
calcium antagonists and calmodulin inhibitors have
been shown to increase both drug levels and
sensitivity in resistant cells. In the P388 model these
effects have been shown both in vitro (Ganapathi &
Grabowski, 1983; Ganapathi et al., 1984; Ramu et
al., 1984; Tsuruo et al., 1981; 1982) and in vivo
(Tsuruo et al., 1983a). Similar effects have also
been shown in L1210 (Yalowich & Ross, 1984),
Ehrlich ascites carcinoma (Slater et al., 1982), Lewis
lung carcinoma, B16 melanoma and two murine
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colon carcinomas (Tsuruo et al., 1983b), and in
human haemopoietic tumour cell lines (Tsuruo et
al., 1983c; Beck, 1983).
PDR has also been reported in human small cell
lung cancer cell lines derived from patients with
progressive disease during chemotherapy (Shoemaker
et al., 1983). In this case, however, the clinical use
of combination chemotherapy means that different
mechanisms of resistance to single agents may be
operative. Rogan et al. (1984) have also shown
that the calcium antagonist verapamil is able to
increase adriamycin cytotoxicity to human ovarian
cancer cell lines derived from patients with tumours
refractory to chemotherapy and in human ovarian
cancer cell lines in which resistance was induced
in vitro.
Clinical data on PDR are not available since
drugs are generally given in combination, which
makes the recognition of any particular pattern of
cross-resistance unlikely. The general relevance of
PDR to both human solid tumours in culture and
the clinical treatment of cancer thus remains to be
established, but it is an exciting prospect that
calmodulin inhibitors and calcium antagonists may
have a role in overcoming clinically observed
tumour drug resistance.
In this paper we present data concerning the
effects of the calcium antagonist verapamil on
adriamycin uptake and cytotoxicity in three human
glioma cell lines with differing sensitivities to the
drug. The data enable a comparison to be made
between the mechanisms of inherent adriamycin
resistance in cell lines derived from human glioma
and that observed in animal models in order to
© The Macmillan Press Ltd., 1986130 S. MERRY et al.
establish the possible relevance to human solid
tumours of observations of PDR in animal models.
Materials and methods
Three human glioma cell lines (G-CCM, G-MCF
and G-UVW) were used in these experiments and
these have been described previously (Merry et al.,
1984). The cell lines grow in culture as monolayers.
The standard growth medium consisted of a
mixture of Ham's FIO and Dulbeco's modified
Eagle's medium (50:50, v/v) with 1 mM glutamine,
10% foetal calf serum and a gas phase of 2% CO2.
In some cases the culture medium was also
supplemented with 50 igml- I gentamycin sulphate.
Cell counting and cell sizing were carried out
using a model ZB, Coulter counter using
trypsinised cells. In the cell sizing experiments the
cells were resuspended in the standard growth
medium at 35+2°C (mean+range). Duplicate
experiments were carried out for each cell line and
14.4,um diameter latex beads were used as
calibration standard.
ADR uptake and efflux experiments were carried
out in Hanks Basal Salts Solution (HBSS) (Flow
Laboratories, Irvine, UK) supplemented with MEM
vitamins (Flow Laboratories), 4.5mM NaHCO3 and
adjusted to pH 7.4. Where the presence of an
energy source was required the medium was
supplemented with 6.1 mM glucose; otherwise the
medium was supplemented with 10mM sodium
azide. When required, the transport medium was
supplemented with 13gM verapamil hydrochloride
(Cordilox IV, Abbot Laboratories, Queensborough,
Kent, UK). Preliminary experiments showed con-
centrations of verapamil greater than 13 uM to be
significantly cytotoxic.
ADR was purchased from Farmitalia Carlo Erba
Ltd (Barnet, Herts, UK). The drug was solubilised
according to the manufacturers' instructions for
injection and stored at -20'C until required
(generally no longer than 1 month after freezing).
This solution was then diluted in culture medium or
HBSS to the required concentrations. At the
highest concentrations in no case did the volume of
diluent added with drug exceed 1% of the final
volume.
[14-14C]-adriamycin hydrochloride was a gift
from Professor F. Arcamone (Farmitalia Carlo
Erba, Via Gionvianni, Nerviano, Milan, Italy). It
was supplied as a pure freeze-dried powder (specific
activity 921Cimg-1) which was solubilised at
10MCiml-1 in PBS and stored at -20°C until
required. For transport experiments this solution
was then further diluted in HBSS to the required
concentration. The volume of diluent added with
the drug was 10% of the final volume.
Drug sensitivity assay
Drug sensitivity assays were carried out using a
modification of the method described previously
(Merry et al., 1984). Briefly, 24-well Linbro plates
were seeded with 5 x 103 cells/well and after 96h
exposed to drug (or drug combinations) for a
period of 72h with drug replacement at 24 and
48h. After a recovery period of a further 120h,
with 3 medium changes, cell number was
determined as cell counts from combined replicate
(2-4) wells. Cell counts of replicate plates showed
control cultures to be in exponential growth
throughout the period of the experiment and the
period of drug exposure to be greater than one
population doubling time.
Drug uptake assay
For drug uptake studies 2 x 104 exponentially
growing cells were seeded into 10mm diameter soda
glass specimen tubes (Scientific Supplies Ltd,
London, UK). The cells were allowed to attach
(24h for G-MCF and G-UVW, and 72h for G-
CCM) and then the monolayers were washed
(3 x 2ml) with ice-cold PBS before 0.2ml of the
appropriately supplemented HBSS transport
medium containing 20M [14C]-ADR was added.
The tubes were then incubated at 37°C or 0°C as
appropriate for 0, 30, 60, 90 and 120min. In each
experiment 3-5 tubes were used per time point.
Uptake of ADR was then assayed as follows.
The cell monolayer was washed with ice-cold
phosphate buffered saline (5x2ml) and 0.2ml of
HBSS transport medium containing glucose was
added to each tube. Following incubation at 37°C
for a further 30min to allow unbound ADR to
equilibrate with the medium, 0.1ml of the
supernatant medium was assayed for radioactivity
by liquid scintillation counting. This sample was
used to calculate the concentration of unbound
ADR. The cell monolayer was then further washed
(3 x 2ml) with ice-cold PBS and bound radioactivity
was assayed by solubilising the cell monolayer in
0.2ml of 0.3 M NaOH containing 1% sodium
dodecyl sulphate (SDS) overnight at room
temperature and scintillation counting of an
acidified sample (0.1 ml).
In preliminary experiments it was shown that the
quantity of radioactivity in the final washings at
each stage was no greater than background levels.
In each experiment replicate (2-6) tubes were
treated in an analogous manner to the experimental
tubes and cell counts of these tubes were used to
express the results as nmolADR 10-6 cells. Where
replicate experiments were carried out (5 cases)
individual results at each time point were combined
to produce single mean values of ADR uptake.
Furthermore, for each of the conditions used (i.e.ADRIAMYCIN RESISTANCE OF HUMAN GLIOMA IN VITRO 131
glucose added, azide added, or glucose and
verapamil added), similar values of ADR uptake
were obtained at 0°C and these data were
combined.
The relatively high concentration of ADR used
in the transport studies was necessitated by the low
specific activity of currently available [14C]-ADR.
To determine the effects of this concentration of
ADR on viability and cell loss from the monolayer,
replicate tubes were exposed for 2h to appropriate
HBSS transport media containing 20pM unlabelled
ADR (100,JM lactose, from the Farmitalia ADR
preparation, was also present in these cases).
Viability was assessed by trypan blue exclusion
before and after ADR treatment using replicate (2-
3) tubes. Cell loss from the monolayer was assessed
by cell counting of replicate (2-4) tubes before and
after ADR treatment. In no instance was a fall in
viability observed and only in the case of
incubation with ADR in the presence of sodium
azide was a slight fall in cell number (10-15%)
noted.
Drug efflux assay
For efflux experiments 1.6 x 106 exponentially
growing cells were seeded into 50ml Pyrex conical
flasks in a volume of 1Oml of the standard growth
medium. The cells were allowed to attach (72h)
before the monolayer was washed (5 x 20ml) with
ice-cold PBS and 5ml of HBSS transport medium
containing sodium azide and without glucose was
added. To label the cells 0.55ml of [14C]-ADR in
PBS was added to give a final concentration of
adriamycin of 20gM and 1 pCiml-1. The flask was
then incubated at 37°C for a period of 2h in a
shaking water bath. Labelling for 2h enabled us to
establish as near as possible steady state conditions
regarding intracellular ADR concentration and
binding without producing unacceptable effects on
viability and cell loss from the monolayer.
ADR efflux was measured after the prelabelled
monolayer had been washed with ice-cold PBS
(5 x 20ml) and 18ml of HBSS transport medium
(containing glucose alone, glucose with verapamil,
or sodium azide) had been added. The transport
medium was added at the appropriate temperature
and the flask was then incubated with shaking at
either 0°C or 37°C as required. Duplicate 400p1
samples of the supernatant were taken at time 0
and I min intervals for a total period of Omin. At
the end of the experiment cell counts of the
monolayer were carried out to enable the results to
be expressed as nmolADR 10-6 cells.
Cell counts of samples of the supernatant
medium at the beginning and end of each
experiment showed cell loss from the monolayer to
be indistinguishable from background (i.e. <1% of
the total) in all cases.
Results
Drug sensitivity ofthe cell lines
The results of the drug sensitivity assays are shown
in Table I. The cell lines chosen for this study
exhibited a range of sensitivity to ADR with G-
MCF being relatively sensitive to the drug and the
cell lines G-CCM and G-UVW being relatively
resistant. The presence of 13uM verapamil caused a
5.1-fold decrease in the ID50 of the most resistant
cell line (G-UVW), a 3.6-fold decrease in the ID50
of the other resistant cell line (G-CCM), but a 1.9-
fold increase in the ID50 of the sensitive cell line
(G-MCF). Figure 1 shows the ADR cytotoxicity
Table I Cytotoxicity data
Cell line
G-CCM G-MCF G-UVW
ID50 of adriamycin (nM) 16 2.1 40
ID50 of adriamycin in
presence of 13JM
verapamil (nM) 4.5 3.9 7.9
% inhibition ofcell growth
by 13gM verapamil 15 2.0 2.5
ID50 of verapamil (uM) 43 24 32
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Figure 1 Effect of verapamil on the sensitivity of the
cell lines resistant to adriamycin: (a) G-UVW and (b)
G-CCM. Each point on the graph represents the result
obtained using the combined cells from 2-4
determinations. (0) Data obtained in the absence of
verapamil; (A) data obtained in the presence of 13pM
verapamil.
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data for G-UVW and G-CCM in detail. In the case
of the cell lines G-MCF and G-UVW this
concentration of verapamil was shown to have
minimal cytotoxicity. For the cell line G-CCM a
broad adriamycin cytotoxicity curve was obtained
in the presence of verapamil and (since the toxicity
caused by 13pM verapamil alone was only 15%)
the effects of verapamil on the cytotoxicity of ADR
appear to be more than additive.
Drug uptake assay
The results of the ADR uptake experiments for the
two resistant cell lines are shown in Figure 2. In no
case has a plateau value of ADR uptake been
reached, but in the case of G-CCM ADR uptake in
the presence of glucose and in the presence of azide
appears to be close to plateau at 120min. Table II
shows the uptake of ADR after 120min. The
results show no relationship between intrinsic ADR
sensitivity and ADR uptake. The effects of either
verapamil or azide on ADR uptake were, however,
related to sensitivity.
Statistical analysis of the results was carried out
using the unpaired Student's t-test, and for the two
most resistant cell lines (G-CCM and G-UVW) the
addition of verapamil was found to produce a
statistically significant (P<0.01 and P<0.05
respectively) increase in the amount of ADR taken
up. For the sensitive cell line (G-MCF) verapamil
had no significant effect on the amount of ADR
taken up (P>0.1). Energy deprivation also
produced a significant increase in the amount of
ADR taken up by the two most resistant cell lines
(P<0.05 for both G-CCM and G-UVW) while
having no effect (P>0.1) in the case of G-MCF.
Table III shows the data for the proportions of
total ADR identified as 'bound' and 'unbound' in
the 2 resistant cell lines. Although both energy
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Figure 2 Total ('bound' plus 'unbo'und') adriamycin
uptake by the resistant cell lines. (a) Cell G-UVW; (b)
Cell line G-CCM. (0) 0°C; (A) in the presence of
6.1mm glucose; (M) in the absence of glucose and
presence of 10mm sodium azide; (A) in the presence
of 6.1mm glucose and 13 M verapamil. Error bars
indicate mean+s.e. Error bars are omitted when their
range would be smaller than the size of the symbol
used to indicate the mean value.
Table II Adriamycin uptake data
Total (bound andunbound)
drug uptake at 120min (nmol106 cells)
Glucose
present,
ID50 Glucose Azide verapamil
Cell line (nm ADR) 0°C present present present
G-MCF 2.1 5.9+1.4a 10.2+1.2 9.7+0.7 11.3 +3.1
G-CCM 16 0.9+0.1 6.7+0.4 8.4+0.3 9.5+0.5
G-UVW 40 2.4+0.2 10.5+1.5 15.2+0.7 15.3+1.1
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Table III Adriamycin binding data for resistant cell lines
unbound ADR Ratio
budAR at 120mm (37OC) bound ADR ( C
Glucose
present
Glucose Azide verapamil
Cell line present present present
G-CCM 0.49 0.49 0.33
G-UVW 0.22 0.64 0.41
deprivation and the addition of verapamil increase
total ADR levels in both cell lines, as described,
only for G-UVW is the proportion of unbound
drug increased by both conditions. For G-CCM the
main effect is an increase in the proportion of
bound drug following the addition of verapamil.
Drug efflux rates
Figure 3 shows the results of experiments to
determine the rate of ADR efflux in G-CCM and
G-UVW. For G-UVW (Figure 3a) in the presence
of energy there is a rapid efflux of ADR from the
cell. Within 3min approximately 5.5nmol 10-6 cells
had been released. This value is equivalent to that
obtained (4.9nmol 10-6 cells) for unbound ADR in
the drug uptake experiments in which labelling
conditions (i.e. in the absence of energy) were
similar to those used here. It would therefore
appear that all the unbound ADR is rapidly lost
from the cells under these conditions. Figure 3a
also shows that the efflux is energy dependent and
that it can be overcome by the addition of
verapamil. For G-CCM (Figure 3b) there are no
major differences in efflux between each of the
conditions used at 37°C. The relationship between
the efflux plateau values was however similar to
that seen in the cell line G-UVW, i.e. energy
present>energy and verapamil present>energy
absent, and the plateau values obtained (2.8-
3.7nmollO-6 cells) represent 1.3, 1.1 and 1.0 fold
respectively of the value obtained for unbound drug
(2.8nmol 10-6 cells) in the drug uptake experiments
when labelling was carried out in the absence of
energy. These results contrast with those obtained
for the cell line G-UVW where only in the case of
efflux in the presence of energy did the amount of
ADR lost correspond to the amount of unbound
drug in the uptake experiments.
Cell size determinations
Duplicate cell sizing experiments for each cell line
gave results which varied from each other by
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Figure 3 Adriamycin efflux from the resistant cell
lines. (a) Cell line G-UVW (b) Cell line G-CCM. Cells
were loaded with adriamycin in the absence of glucose
and presence of 10mM sodium azide. (0) 0°C in the
presence of 6.1mm glucose; (A) 37°C in the presence
of 6.1 mm glucose; (M) 37°C in the absence of glucose
and presence of 10mM sodium azide; (A) 37°C in the
presence of 6.1 mm glucose and 13gM verapamil. Each
point represents the mean of duplicate determinations.
The range of the duplicates was always < 15% of their
mean value.
< 10% of their mean value. Furthermore, the
results were similar for each of the cell lines. For
G-MCF, G-UVW and G-CCM respectively the
median cell volume was 2860, 3160 and 2670jim3
with 73, 84 and 76% of the total populations
within the range of volumes 1050-4710pm3 (i.e.
radii 6.3-10.4pgm).134 S. MERRY et al.
Discussion
We have investigated the relationship between
intracellular accumulation of ADR and ADR
cytotoxicity for 3 glioma cell lines. One of the cell
lines (G-MCF) was shown to be relatively sensitive
to ADR whilst the other two (G-CCM and G-
UVW) were relatively insensitive to ADR. A
finding which confirms our previous observations
(Merry et al., 1984).
In our studies of ADR uptake we found no
relationship between ADR accumulation and
inherent sensitivity (Table II), nor could differences
in accumulation (expressed as nmoll10 6 cells) be
related to differences in cell size. A similar
observation has been made by Chang and Gregory
(1985) for a pair of rodent pancreatic adeno-
carcinoma cell lines. Furthermore Kessel and
Wilberding (1985) have shown that changes in
intracellular daunorubicin (an ADR analogue)
accumulation could not totally account for the level
of resistance observed in P388 leukaemia cells.
We have shown for the two resistant glioma cell
lines that a concentration of verapamil with low
cytotoxicity is able to increase significantly ADR
sensitivity (up to 5.1-fold decrease in ID50). The
increase in sensitivity was greatest in the most
resistant cell line (G-UVW) and this effect was not
observed in the most sensitive cell line (G-MCF).
These data are consistent with findings in a number
of animal tumour models and in human haemo-
poietic tumour cell lines in culture. Verapamil
has also been reported to increase the sensitivity
of both human ovarian cancer cell lines (Rogan
et al., 1984) and of non-small cell lung cancer
cell lines (Fetherston et al., 1985) to ADR in vitro.
In both cases it was shown that the effect of
verapamil was greatest in cell lines most resistant to
the drug.
The effects of energy-deprivation or verapamil
addition were related to the intrinsic sensitivity of
the cell line with both these treatments producing
increased drug accumulation in two resistant cell
lines, but not in' a sensitive cell line (Table II). The
same concentration of verapamil also increased the
cytotoxicity of ADR in the 2 resistant cell lines, but
not the sensitive cell line (Table I). These results
suggest that intracellular drug levels may have a
role in determining the ADR sensitivity of
individual glioma cell lines in culture although there
may well be other mechanisms of anthracycline
resistance that are affected by verapamil.
The effects of verapamil on cytotoxicity (3.6-5.1
fold) in the 2 resistant cell lines contrast with 0.42-
0.46 fold increase in drug levels seen in the ADR
uptake experiments. While these results may
indicate that verapamil is overcoming* other
mechanisms of resistance in addition to increasing
intracellular drug levels, direct comparison between
the 2 assays cannot be made due to the different
ADR concentrations used and periods of drug
exposure.
That there may be multiple mechanisms of
resistance to ADR is further indicated in G-CCM
by the broad cytotoxicity curve for ADR in the
presence of verapamil (Figure lb). This shape
contrasts with the apparently sigmoidal cytotoxicity
curves of G-UVW, possibly indicating a single
mechanism of resistance to adriamycin which is
sensitive to verapamil.
Our data on ADR binding and efflux show
differences between the 2 resistant cell lines. For G-
UVW energy deprivation or verapamil addition
produced an increase in the level of unbound ADR
(Table III). The rate of ADR efflux was greatest in
the presence of glucose alone. This rate was greatly
decreased both in the absence of glucose and in the
presence of verapamil; a result consistent with the
presence of an active efflux mechanism which can
be inhibited by verapamil. Furthermore, the
changes in the level of unbound ADR seen in the
uptake experiments could be accounted for by the
degree of active efflux seen.
An energy dependent drug efflux mechanism
which can be inhibited by verapamil and results in
lower intracellular drug levels, has been demon-
strated in a number of tumour models in which
resistance to either ADR or daunorubicin had
been induced (for review see Kaye & Merry, 1985).
On the other hand, for G-CCM efflux in the
presence of energy appeared to be greater than the
amount of unbound ADR (based on the ADR
uptake experiments). Thus it is conceivable that, as
Beck (1983) has suggested for resistant cells, in G-
CCM release of drug from binding sites may be
energy-dependent.
Clearly some of the ADR released into the
incubation medium could originate from dead cells
released from the monolayer. However, we have
shown that less than 1% of the cells were lost in
this manner. Since the total amount of ADR taken
up by the cells was between 8.4 and 15.3nmol 10-6
cells the loss of 1% of the cells cannot account for
an ADR efflux of between 0.8 and 5.4nmollO-6
cells.
These results indicate that ADR resistance may
be multifactorial in nature, but they do form part of
a growing body of evidence that a component of
inherent ADR resistance may (in some cases) be
due to a mechanism similar to that observed in
animal models where resistance has been induced,
i.e. the presence of active drug efflux which can be
overcome by verapamil. The relevance of these
findings to human solid tumour masses (either asADRIAMYCIN RESISTANCE OF HUMAN GLIOMA IN VITRO 135
xenografts or in the clinic) however remains to be
established and the results of studies in these areas
are eagerly awaited. A potential role for verapamil
in overcoming tumour drug resistance in the clinic
is also indicated.
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